Glucagon-like peptide-1 (GLP-1) receptor agonist; synthetic exendin-4
Exenatide
Approvedaka Byetta, Bydureon, exendin-4
Exenatide is an approved GLP-1 therapy for type 2 diabetes and was the first drug in its class. It is a synthetic form of exendin-4, a peptide originally identified in the saliva of the Gila monster, that shares partial sequence homology with human GLP-1. Immediate-release (Byetta) and once-weekly extended-release (Bydureon) formulations lower HbA1c and body weight; the EXSCEL cardiovascular outcomes trial found it did not increase cardiovascular risk. In recent years the originator has discontinued supply of some exenatide formulations in certain markets.
Compare
Mechanism
In plain terms, exenatide mimics a gut-hormone-like peptide that lowers blood sugar and reduces appetite. Technically, it is a synthetic exendin-4 that agonizes the GLP-1 receptor while resisting degradation by the enzyme DPP-4, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. The extended-release formulation encapsulates exenatide in biodegradable microspheres to allow once-weekly dosing.
Regulatory Status by Region
- United States (FDA)Approved. Byetta (exenatide twice daily) for type 2 diabetes (2005), the first GLP-1 receptor agonist approved, and Bydureon (extended-release, once weekly) (2012).
- Australia (TGA)Registered on the ARTG for type 2 diabetes, available on prescription.
- European Union (EMA)Authorized: Byetta (2006) and Bydureon (2011) for type 2 diabetes.
- WADANot prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.
Key Studies
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL; Holman et al.) (opens in a new tab) (N Engl J Med 2017;377:1228-1239; DOI 10.1056/NEJMoa1612917; PMID 28910237)
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1; Drucker et al.) (opens in a new tab) (Lancet 2008;372:1240-1250)
Related Clinical Trials
- A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyN/A · Not Yet Recruiting
- Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma LocalizationN/A · Recruiting
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsN/A · Recruiting
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisPhase 2 · Recruiting
- A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusEARLY_Phase 1 · Recruiting
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)N/A · Active Not Recruiting
- Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantPhase 1 · Completed
- Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.N/A · Recruiting
Related News & Research
- Published Exchange in Brain Disputes Whether a Genetic Marker Predicts GLP-1 Drugs' Effect on Parkinson's
- This Week in Peptide Research: Mitochondrial Peptides, a Bone Density Study After Knee Replacement, and a Quiet Week for GLP-1 Trials
- This Week in Peptide Research: GLP-1 Mechanism Studies, LL-37 Engineering Advances, and Kisspeptin's Reach Beyond Reproduction
- This Week in Peptide Research: An Online-Sourced Retatrutide Safety Case, Tissue-Repair Reviews, and Mitochondrial Peptide Studies
- Large Matched-Cohort Study Finds Modest Retinopathy Risk With GLP-1 Drugs, No Significant Link to Rare Optic Nerve Disorder
Latest research
- Occult Abdominal Para-Aortic Ectopic Insulinoma Localized by 18F-NOTA-Exendin-4 PET/CT. (opens in a new tab)
Clinical nuclear medicine · Oct 20, 2026
- 68Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging. (opens in a new tab)
The Journal of clinical endocrinology and metabolism · Oct 16, 2026
- Efficacy of low-dose pioglitazone in combination with exenatide on glucose control in patients with T2DM. (opens in a new tab)
BMJ open diabetes research & care · Oct 13, 2026
Common Questions
- What is Exenatide?
- Exenatide is a GLP-1 receptor agonist and a synthetic version of exendin-4, marketed as Byetta (twice daily) and Bydureon (extended-release, once weekly) for type 2 diabetes. It was the first GLP-1 receptor agonist approved (FDA 2005) and is EMA-authorized and TGA-registered; its cardiovascular safety was evaluated in the EXSCEL trial. It is a prescription medicine.
- Is Exenatide approved for medical use?
- Exenatide is approved for one or more medical uses in at least one major jurisdiction. United States (FDA): Approved. Byetta (exenatide twice daily) for type 2 diabetes (2005), the first GLP-1 receptor agonist approved, and Bydureon (extended-release, once weekly) (2012). European Union (EMA): Authorized: Byetta (2006) and Bydureon (2011) for type 2 diabetes. Australia (TGA): Registered on the ARTG for type 2 diabetes, available on prescription.
- How does Exenatide work?
- In plain terms, exenatide mimics a gut-hormone-like peptide that lowers blood sugar and reduces appetite. Technically, it is a synthetic exendin-4 that agonizes the GLP-1 receptor while resisting degradation by the enzyme DPP-4, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety.
- Is Exenatide legal in Australia?
- Exenatide in Australia (TGA): Registered on the ARTG for type 2 diabetes, available on prescription.
- Is Exenatide banned in sport?
- Exenatide under the World Anti-Doping Agency (WADA) code: Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.